

**Left Atrial Appendage Occlusion versus Novel Oral Anticoagulation for Stroke Prevention  
in Atrial Fibrillation – One Year Survival**

*Tiosano et al.*

Supplementary material

**Contents**

Table S1 – Baseline characteristics of study participants with CrCl <= 60 mL/min ..... 2

Table S2 – The association between LAAO vs. NOACs and 1-year mortality – stratification by distinct groups. .... 3

Table S1 – Baseline characteristics of study participants with CrCl ≤ 60 mL/min

	<b>LAAO</b> N=62	<b>NOACs</b> N=217	<b>P</b>
<b>Age</b>	79.0±7.97	79.5±11.5	0.736
<b>Sex: Male</b>	31 (50.0%)	121 (55.8%)	0.510
<b>Hypertension</b>	50 (80.6%)	172 (79.3%)	0.953
<b>Diabetes Mellitus</b>	26 (41.9%)	81 (37.3%)	0.610
<b>Ischemic Heart Disease</b>	36 (58.1%)	108 (49.8%)	0.313
<b>Congestive Heart Failure</b>	25 (40.3%)	86 (39.6%)	1.000
<b>Ejection fraction (%)</b>	52.8±7.69	52.6±11.1	0.873
<b>Prior bleeding</b>	46 (74.2%)	168 (77.4%)	0.719
<b>Prior stroke or TIA</b>	31 (50.0%)	85 (39.2%)	0.168
<b>CrCl</b>	35.8±20.0	37.3±17.0	0.610
<b>CHA<sub>2</sub>DS<sub>2</sub>-VASc</b>	4.39±1.51	4.16±1.64	0.310
<b>CHA<sub>2</sub>DS<sub>2</sub>-VASc =&gt; 4</b>	47 (75.8%)	157 (72.4%)	0.705
<b>HAS-BLED</b>	4.13±1.18	4.38±1.27	0.153
<b>HAS-BLED =&gt; 4</b>	45 (72.6%)	185 (85.3%)	0.034
<b>Prior Aspirin treatment</b>	23 (37.1%)	74 (34.1%)	0.775

LAAO: Left Atrial Appendage Occlusion; NOACs: Novel Oral Anticoagulants; TIA: Transient Ischemic Attack; CrCl: Creatinine Clearance, mL/min

Table S2 – The association between LAAO vs. NOACs and 1-year mortality – stratification by distinct groups.

	<b>LAAO</b>	<b>NOACs</b>
<b>Under age 80</b>	6/174 (3.45%)	2/62 (3.23%)
<b>Age 80 plus</b>	26/168 (15.5%)	3/52 (5.77%)
<b>Males</b>	14/202 (6.93%)	4/70 (5.71%)
<b>Females</b>	18/140 (12.9%)	1/44 (2.27%)
<b>CrCl 60 plus</b>	3/125 (2.40%)	3/52 (5.77%)
<b>CrCl under 60</b>	29/217 (13.4%)	2/62 (3.23%)

LAAO: Left Atrial Appendage Occlusion; NOACs: Novel Oral Anticoagulants; CrCl: Creatinine Clearance